

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12P 21/00, C07H 15/12 C07K 13/00	A1	(11) International Publication Number: WO 90/04641 (43) International Publication Date: 3 May 1990 (03.05.90)
(21) International Application Number: PCT/US89/04732 (22) International Filing Date: 20 October 1989 (20.10.89) (30) Priority data: 263,648 27 October 1988 (27.10.88) US (71) Applicants: THE BOARD OF TRUSTEES OF THE LE- LAND STANFORD JUNIOR UNIVERSITY [US/ US]; Stanford University, Stanford, CA 94305 (US). SCLAVO, S.P.A. [IT/IT]; Via Fiorentina, 1, I-53100 Sie- na (IT). (72) Inventors: RELMAN, David, A. ; 785 Roble, No. 5, Menlo Park, CA 94025 (US). DOMENIGHINI, Mario ; Via Colombini, 9, I-53100 Siena (IT). RAPPUOLI, Rino ; Via Calamandrei, 39, Quercegrossa, I-53035 Monteriggo- ni (IT). FALKOW, Stanley ; 8 Longspur, Portola Valley, CA 94025 (US).		(74) Agent: ROWLAND, Bertram, I.; Leydig, Voit & Mayer, 350 Cambridge Avenue, Suite 200, Palo Alto, CA 94306 (US). (81) Designated States: AT (European patent), AU, BE (Euro- pean patent), CH (European patent), DE (European pa- tent), DK, FI, FR (European patent), GB (European pa- tent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent). Published <i>With international search report.</i>
(54) Title: FILAMENTOUS HEMAGGLUTININ OF <i>B. PERTUSSIS</i> (57) Abstract Nucleic acid and protein compositions are provided from <i>B. pertussis</i> which may find use in diagnosis, prevention and therapy of whooping cough. Particularly, an open reading frame encoding filamentous hemagglutinin precursors provided, with the intact protein for the filamentous hemagglutinin portion thereof, can be expressed in a wide variety of hosts, for use in the production of antibodies, for immunodiagnosis or therapy, or as vaccines for prophylactic purposes.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Fasso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

-1-

5 FILAMENTOUS HEMAGGLUTININ OF B. pertussisCROSS REFERENCE TO RELATED APPLICATIONS

10 This application is a continuation-in-part of
Application Serial No. 263,648, filed October 27, 1988,
which is incorporated herein by reference.

INTRODUCTION15 Technical Field

This invention relates to the gene encoding
filamentous hemagglutinin of B. pertussis, the protein
product and the use of the gene and the product for
developing vaccines by genetic engineering techniques.

20

BACKGROUND

Bordetella pertussis is a small gram negative
bacillus found only in humans. It is the etiologic
25 agent of the childhood disease whooping cough, also
known as pertussis. In susceptible individuals, the
disease may progress to a serious paroxysmal phase.
Violent and spasmodic coughing occurs, with the patient
being subject to secondary injury from the hypoxia and
30 convulsions attendant with the coughing paroxysms.
Secondary infections, encephalopathy and death may
occur. The discrete molecular moiety that has been
associated with the severe effects in the paroxysmal
stage of the disease is pertussis toxin (PTX). PTX has
35 been reported under a variety of names, including
lymphocytosis promoting factor, histamine sensitizing
factor and islet-activating protein.

Another protein, filamentous hemagglutinin (FHA) is a surface associated protein expressed by B. pertussis under the control of a trans-acting vir locus. FHA, while poorly characterized, is thought to act as a major adhesion and immunodominant antigen in the course of human infection. This protein appears as a heterogeneous collection of polypeptide species on sodium dodecylsulfate-polyacrylamide gel electrophoreses, ranging from approximately 60 to 220 kDa (kilodaltons). It is likely that most of the smaller, commonly seen protein gel bands represent degradation products of a dominant 220kDa species. Electron microscopy of this protein reveals a filamentous structure with dimensions of 2nm by 40-100nm.

It has been suggested that FHA is one of the most important factors mediating the bacterial-eukaryotic cell adhesive interactions. Furthermore, FHA stimulates an immune response in humans following clinical disease and acts as an immunoprotective antigen in a model system employing aerosol challenge of immunized mice. Although less effective than PTX when used alone, FHA and PTX together demonstrate a synergistic immunoprotective effect.

RELEVANT LITERATURE

A description of the B. pertussis hemagglutinin protein may be found in Irons et al., J. Gen. Microbiol. (1983) 129:2769-2778; Arai and Sato, Biochem. Biophys. Acta (1976) 444:765-782; and Zhang et al., Infect. Immun. (1985) 48:422-427. Physiological properties are described by Tuomanen and Weiss, J. Infect. Dis. (1985) 152: 118-125; Lenin et al., FEMS Microbiol. Lett. (1986) 37:89-94; Urisu et al., Infect. Immun. (1986) 52:695-701; Redd et al., J. Clin. Microbiol. (1988) 26:1373-1377; Oda et al., J. Infect. Dis. (1984) 150:823-833; Robinson and Irons, Infect.

Immun. (1983) 40:523-528; Sato and Sato, ibid. (1984) 46:415-421; and Ad Hoc Group for the Study of Pertussis Vaccines, Lancet i (1988) 955-960.

5 Cloning of the filamentous hemagglutinin structural gene or fragment thereof has been reported by Brown and Parker, Infect. Immun. (1987) 55:154-161; Reiser et al., Dev. Biol. Stand. (1985) 61:265-271; Mattei et al., FEMS Microbiol. Lett. (1986) 36:73-77 and Stibitz et al., J. Bacteriol. (1988) 170:2904-2913.

10 Chemical analysis of the filamentous hemagglutinin has been reported by Sato et al., Infect. Immun. (1983) 41:313-320.

SUMMARY OF THE INVENTION

15 DNA sequences encoding at least a portion of the B. pertussis fhaB gene, genetically engineered products including such sequences, the expression products of such sequences, and cells containing such genetically engineered sequences are provided for use
20 in the diagnosis, prophylaxis and therapy of whooping cough.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

The subject invention concerns nucleotide
25 sequences associated with the filamentous hemagglutinin protein of B. pertussis and their use in the diagnosis prophylaxis and therapy of whooping cough or pertussis. The open reading frame is about 10 kbp (specifically about 10789 bp) as the sequence set forth
30 in the experimental section. It encodes a protein of about 368 kDa (about 3597 amino acids), comprising an N-proximal fragment of 230 kDa, which N-proximal fragment is divided by proteolysis into two polypeptide fragments of about 98 and 140 kDa at an arginine-rich
35 peptide sequence RRARR, which are the N-terminal and C-terminal fragments, respectively. This sequence may act as a proteolytic cleavage site. The overall

polypeptide is basic, has a relatively high charge density, a pK_I of 9.65 and a net charge of +19. Alanine and glycine constitute 27% of the total residues, while only 3 upstreams are present. The last
5 350 amino acids provide a highly basic region (charge +32; pK_I 11.3) rich in proline (17%). At amino acid position 1097 (defined by the start of translation at 253bp from the left-hand EcoRI site) and again at position 2599 is the tripeptide sequence RGD. This
10 sequence is known as a "cell recognition site" for the interaction of fibronectin and other eukaryotic extracellular matrix proteins with certain eukaryotic cell receptors, particularly mammals, and may function in a similar manner in FHA mediated bacterial adherence.

15 The gene appears to be located adjacent to the vir locus. In the direction defined by transcription an apparent regulatory gene fhaA lies about 2-5 kb downstream from fhaB, followed by the gene fhaC, also believed to be a regulatory gene, again in the
20 downstream direction from fhaA. The beginning of the ORF is separated by approximately 430 bp from the first of the bng genes bngA. The gene begins at position 253 from the left at the pDR_1 EcoRI site and ends at position 11041 with a TAG codon.

25 The fhaB gene is characterized by having a high GC content, namely about 67.5%. In addition, there is a series of tandem direct nucleotide repeats of the pattern ABABA in the region from nucleotide 1468 to nucleotide 1746, with the G of the sequence reported
30 in the Experimental section being nucleotide 1. An unusual alternating repeat (PK)₅ begins at residue 3477. The sequence VEVVPRKVET at position 3319 is repeated at position 3350. Transcriptional initiation appears to occur 70-75 bp upstream of the ORF.

35 Fragments of the open reading frame of at least about 15 bp, more usually at least about 50 bp, and usually at least about 100 bp may find use in a

variety of ways. The fragments may be used for diagnostic purposes, as probes in hybridizing to DNA or RNA for detecting the presence of B. pertussis or the like. Use of Southern, Northern, dot-blot, or other techniques may be employed. The fragments may be used for encoding peptides of at least about 9 amino acids (27 bp) usually at least about 12 amino acids.

The fragments may also be used in the anti-sense direction to modulate the amount of the expression product of the fhaB gene, where such modulation may be of interest. Thus, the infectious ability of the organism may be modulated and/or attenuated by reducing the presence of the filamentous hemagglutinin protein on the surface of the organism.

Fragments of interest of the fhaB gene include those fragments associated with the expression of the 98 kDa protein and the 230 kDa protein. Using the numbering as set forth in the sequence provided in this application, the fragment for the 98 kDa protein would terminate between nucleotides 3402 and 3502, usually between 3451 and 3474. The 230 kDa protein is initiated in that region and terminates at about nucleotide 9624. When FHA is originally isolated and purified from B. pertussis liquid culture supernatant using standard techniques there are often 3-4 bands seen on SDS-PAGE, with polypeptide species of 230, 140, 125 and 98 kDa. With increasing time of storage, two new species appear, 75 and 58 kDa with concurrent fading of the 230 kDa band and intensification of the 125 and 98 kDa bands. An identical N-terminal sequence is observed for the 140 and 125 kDa fragments: A-L-R-Q-D-F-F-T-P-G-S-V-V-V-R-A-Q-G-N. This peptide is encoded beginning at position 1074, immediately downstream from a proposed proteolytic cleavage site R-R-A-R-R, and terminating at position 1131. Also of interest is the repeat sequence, where the sequence should have at least two repeats, preferably three

repeats, and the fragment will be at least about 60 nucleotides, more usually about 100 nucleotides, and may be 278 nucleotides or more, usually not exceeding about 300 nucleotides of the open reading frame, the latter encompassing the entire repeat region. The repeats do not have perfect homology, but show a high degree of conservation.

Regions of interest will be those encoding amino acid sequences 1211 to 1216 (E-A-R-K-D-E), 1876 to 1881 (R-K-D-E-H-R) and 3075 to 3080 (S-K-Q-D-E-R), and adjoining amino acid sequences, extending up to 100 amino acids, usually up to 50 amino acids in either direction, but particularly including at least 3 amino acids of the sequences described above. DNA sequences of interest may include fragments of 3490 to 3590, 3840 to 3940, 5840 to 5940, 9440 to 9540, and fragments of at least 15bp, more usually at least 25bp thereof. The fragment from about 5625 to 5780 does not appear to have any features of interest and may be excluded, unless joined to one of the fragments indicated above.

Antisera prepared against the B. pertussis FHA protein cross-reacts with polypeptide species of B. parapertussis and B. bronchiseptica. Antisera binding to the expression products of the regions 2836-3786 nt, 5212-7294 nt and 6393-8080 nt bound to peptides of parapertussis, while only the antisera of the first two bound to peptides of brochiseptica.

The subject protein or any portion thereof may be prepared in any convenient host, preferably prokaryotic. By transforming an appropriate host with the expression construct, the host will express the polypeptide of interest, which may then be isolated or, as appropriate, the host may be isolated containing the subject protein or portion thereof and used as a vaccine.

The expression construct or cassette will employ a transcription initiation region, the structural gene for the polypeptide to be expressed, and and a transcriptional termination region. The transcriptional initiation region may include only the RNA polymerase binding site or may also include an enhancer or operator to provide for increased expression of the subject protein or portion thereof, or inducible expression of the subject protein or portion thereof.

A large number of transcription initiation regions are known which are active in one or more prokaryotic hosts, such as the lambda left or right promoters, the lac promoter, the trp promoter, the tac promoter, omp promoter, metallothionein promoter, etc. The natural promoter may also find use. The particular promoter will be chosen to provide for efficient expression in accordance with the selection of the host cell line.

For the most part, prokaryotic host cell lines will be used to provide for efficient expression of the filamentous hemagglutinin or portion thereof, integrity of the expression product, ease of isolation of the expression product, and in some situations, the ability to use the host without isolation of the protein, using the transformed host as the vaccine. Various organisms may be used which may provide for an immune response not only to the subject proteins or portions thereof, but also to other pathogens, so that the vaccine will result in immune protection, not only against the B. pertussis organism but also against disease caused by other pathogens.

Various host organisms which may be used include various gram negative organisms, such as E. coli, Salmonella, Yersinia, Pseudomonas, Bordetella, such as the species avium, bronchiseptica, para-

pertussis and pertussis, where the last two are particularly preferred.

A previously indicated sequence analysis of the subject protein indicates a guanine plus cytosine content considerably higher than that of the traditional E.coli cloning host (approximately 50%). Therefore, for the most part, the host will desirably have a high guanine plus cytosine content in its genome, preferably at least 60%, more preferably 65%. However, one may use synthetic portions to reduce the ratio of guanine and cytosine for use in organisms lacking a preference for GC.

Various replication systems are available for use in the various host species. For the most part, the vectors will include not only a functional replication system but a marker for selecting transformants comprising the subject structural gene or portion thereof. While it is usually desirable to employ either a plasmid or virus which is stably maintained as a vector without lysogeny, to enhance the efficiency of expression by having a multicopy replication system which is stable in the host, this is not necessary. Thus, one can transform with bare DNA comprising the expression cassette in combination with a marker for selection, where the marker may be joined to the expression cassette or be independently present in the transformation media. In some situations, a vector will be employed which does not have a stable replication system for the expression host. In this manner, selection can be carried out to insure that integration has occurred by selecting for those cells containing the marker.

A wide variety of markers may be used which include antibiotic resistance, resistance to heavy metals, imparting prototrophy to an auxotrophic host, or the like. The particular choice of marker is not critical to this invention, but will be selected for

efficiency in selection and efficiency in production of the subject protein or portion thereof.

Depending on the manner of transformation, as well as the host, various other functional capabilities may be provided in the vector. For example, transfer capability may be provided which allows for conjugation in conjunction with a helper plasmid, where once transferred to the recipient host, the vector may no longer be transferred to other hosts. For example, the rlx sequence may be employed, particularly from the P-1 incompatibility group. In addition, the cos site may be employed from bacteriophage lambda. Other markers of interest may include a gene which renders an antibiotic resistant strain sensitive.

The termination region is not critical to this invention and any convenient termination region may be used. The native termination region may be employed or a termination region which is normally associated with the transcription initiation region or a different region. The fact is that many transcription termination regions have been employed and are generally available and may be used with advantage.

The host may be transformed in any convenient way. By using bare DNA, calcium phosphate precipitated DNA may be employed for transformation. Alternatively, conjugation may be employed using a helper plasmid, where a transfer gene is provided in a vector. In some instances, it may be desirable to employ a bacteriophage vector, where the host cell will be transduced or transfected. The technique for introducing the expression cassette comprising the subject gene or portion thereof is not critical to this invention and various alternative protocols find ample exemplification in the literature.

The subject gene may also be subject to various lesions or mutations. For example, the sequence RRARR may be substituted, deleted, or modified

so as to remove the peptidase cleavage site. Thus, the protein would be retained substantially intact, with the two potential fragments fused together. This protein could find a variety of uses. Other mutations
5 may include the removal of the upstream portion of the gene, so as to leave only the sequence that is downstream from the RRARR sequence, where an initiation codon may be introduced at the appropriate site. In addition, mutagenesis of an RGD region may cause
10 altered interactions with eukaryotic target cells and perhaps an altered host immune response, both of which may prove useful for disease therapy or prophylaxis.

Mutation can be achieved in a variety of ways using in vitro mutagenesis, primer repair, the
15 polymerase chain reaction, restriction site deletions, insertions, or the like. The particular manner in which the subject gene is modified is not critical to this invention and any conventional technique may be employed which provides for the desired substitutions,
20 deletions or insertions.

The subject gene can be obtained by EcoRI digestion of the plasmid pUW21-26. The resulting 10 kb EcoRI fragment contains the open reading frame of 9375 bp. This fragment may be manipulated at its 5'
25 terminus in a variety of ways. By employing Bal 31 digestion, the sequence may be resected to remove all or a portion of the non-coding region 5' of the initiation codon. Alternatively, one may restrict either upstream or downstream from the initiation
30 codon, where the nucleotides removed by restriction downstream from the initiation codon may be replaced with an appropriate adapter. In this manner, the subject sequence may be inserted into a polylinker downstream from a transcriptional initiation regulatory
35 region and be under the transcriptional initiation regulation of such region.

The subject compositions, both nucleotides and proteins, may find both diagnostic and therapeutic use. For diagnostic use, as already indicated, the sequences may be used to detect the presence of nucleic acid sequences which duplex with the subject sequences as indicative of the presence of B. pertussis.
Alternatively, the protein or portion thereof may be used in diagnostic assays, as a labeled or unlabeled reagent for detection of antibodies to the filamentous hemagglutinin in a blood sample or the presence of filamentous hemagglutinin protein in a blood or tissue sample.

Intact protein or portion thereof may be used to prepare antibodies which may be used in diagnosis, prophylaxis or therapy. The antibodies may be polyclonal or monoclonal, preferably monoclonal. Desirably, neutralizing antibodies will be obtained. Antibodies may be mouse antibodies, human antibodies, chimeric antibodies, e.g., mouse variable region and the human constant region, or the like. Of particular interest are those constant regions which bind to complement, such as IgM and IgG isotypes. The antibodies may be used for passive immunization or for treatment in accordance with conventional ways.

The subject compositions also find use as vaccines, as the protein, by itself or in combination with other proteins, e.g., acellular compositions, as cellular compositions in a pertussis or non-pertussis host, in purified or semi-purified form or the like. Desirably, the subject compositions are used in conjunction with a modified pertussis toxin, where the toxin no longer has ADP-ribosyltransferase activity, particularly subunit A. This can be achieved by using ptx3201 as described in Black et al., Science (1980) 240:656-659. By introducing the subject gene under the transcriptional initiation regulatory control of a constitutive promoter or an inducible promoter, which

is not regulated by the normal pertussis transcriptional regulation of the filamentous hemagglutinin gene, one can provide for the enhanced presence of the subject protein on the surface of the B. pertussis cell. In this way, an enhanced immune response may be achieved in response to vaccinating either live or dead organisms.

Because of the various ways in which the subject composition may be administered, the amount administered will vary widely. In addition, the amount of the vaccine will vary in accordance with the nature of the administration, the frequency of the administration, the presence or absence of antigen, the nature of antigen, or the like

The manner of administration may be oral, peritoneal, subcutaneous, intravascular or the like. Usually, an inert carrier is employed, such as sugar, water, aqueous ethanol, phosphate buffered saline, saline, or the like. Adjuvants include aluminum hydroxide, vegetable oils, bacterial toxins, etc. The amount of the active ingredient will generally be in the range of about 25 to 75 µg/kg for a single human dose. Pertussis vaccines have been used previously, and prior usage may be used as a guide for the dosage employed. See, for example, Developments in Biological Standardization, supra.

The following examples are offered by way of illustration and not by way of limitation.

30 EXPERIMENTAL

Materials and Methods

Bacterial Strains and Plasmids. B. pertussis strain BP536 is a spontaneously-occurring streptomycin resistant mutant of the virulent phase (I) parental strain BP338. BP537 is an avirulent phase variant of BP536. The isolation of the Tn₅ mutant BP353 has been

previously described, Weiss et al., Infect. Immun. (1983) 42:33-41; the transposon insertion site has been mapped more recently (Stibitz et al., 1988, supra) BP338 Tn5-25 carries a Tn5 insertion mutation within the 2.4 kb BamHI segment of fhaB (Stibitz et al., 1988, supra). BP-TOX6 (available from R. Rappuoli) is a derivative of BP536 with a deletion of the pertussis toxin operon and the substitution of a kanamycin resistance cassette at that location. BP-B52 (available from F. Mooi) is a BP536 derivative which carries insertion mutations which inactivate the fim2 and fim3 genes independently. E. coli strains JM101 and SM10 have been described elsewhere (Messing, Recomb. DNA Tech. Bull. (1979) 2:43-48; Simon et al., Bio/Technology (1983) 1:784-791). Cosmid pUW21-26 is a derivative of pHC79 (Hahn and Collins, Gene (1980) 11:291-298) with an approximately 45 kb insert, containing the cloned vir and fha loci from BP338 (Stibitz, 1988, supra). The construction of plasmid vector pRTP1 has been described (Stibitz et al., Gene (1986) 50:133-140).

Cloning of fhaB and Construction of fhaB Deletion Mutants.

The filamentous hemagglutinin (FHA) structural gene, fhaB, was cloned on a 10 kb EcoRI fragment from cosmid pUW21-26 into the vector pRTP1, creating the recombinant plasmid pDR1. An in-frame partial deletion of fhaB was constructed by re-ligating a pool of BamHI partial digests of pDR1. Plasmids were screened for the loss of an internal 2.4 kb BamHI fragment. The resultant plasmid was designated pDR101.

Bacterial Conjugations and Allelic Exchange

The technique for conjugal transfer of pRTP1 derivatives from E. coli to B. pertussis has been described (Stibitz et al., 1986, supra). The partially

deleted copy of fhaB was exchanged for the wild type allele in B. pertussis BP536 in two steps. First, the E. coli donor, SM10(pDR101), was mated with a B. pertussis recipient, BP536 Tn5-25, which carries a
5 selectable marker within the fhaB fragment to be deleted. Sm^R Ap^R exconjugants were then plated on media containing Sm alone and screened for the loss of Km resistance, indicating a second crossover event and acquisition of the mutant allele.

10

DNA Sequencing and Sequence Analysis

The 10 kb EcoRI fragment containing fhaB was subcloned as three separate BamHI fragments as well as random one to three kb Sau3A fragments in M13mpl8 and
15 M13mpl9 (Yanisch-Perron et al., Gene (1985) 33:103-119), pEMBL18 and -19 (Dente et al., Nucleic Acids Res. (1983) 11:1645-1655), or Bluescript (Stratagene, San Diego, CA) vectors. DNA inserts were sequenced by the dideoxy chain-termination method (Sanger et al., Proc.
20 Natl. Acad. Sci. USA (1977) 74:5463-5467), using either Klenow fragment or Sequenase (U.S. Biochemical Corporation, Cleveland, Ohio). Synthetic oligonucleotide primers were designed in order to extend sequence reading across large cloned inserts.
25 Assembly of the nucleotide sequence was performed using the software package of the University of Wisconsin Genetics Computer Group (Madison, WI). Further analysis of the completed nucleotide and predicted peptide sequences was performed, using both this
30 package as well as PC/GENE (Intelligenetics, Mountain View, CA).

Hemagglutination

The ability of B. pertussis strains to
35 agglutinate sheep erythrocytes was assayed in conical pointed-bottom wells of polystyrene Microtiter plates (Dynatech Laboratories, Alexandria, VA). The strains

were grown for two to three days on Bordet-Gengou plates, washed twice in phosphate-buffered saline, and resuspended to an OD₆₀₀ of 10 (1.7×10^{10} cells/ml). The first well of a microtiter plate received 100 μ l of this cell suspension, following which the bacteria were two-fold serially diluted 11 times. Sheep erythrocytes were added to each well as 50 μ l of a 0.5% PBS-washed suspension. The plates were left at room temperature for three to four hours during which time nonagglutinated erythrocytes slid down the well bottoms forming a dark pellet. Hemagglutinating (HA) activity was expressed as the inverse of the highest dilution without significant pellet formation.

15 Western Immunoblots

Polyacrylamide gel electrophoresis was performed in the presence of sodium dodecylsulfate with a 10% separating gel and 20 μ l of boiled (OD₆₀₀=10) B. pertussis cell suspension with sample buffer. Transfer of protein to nitrocellulose membrane followed the procedure of Towbin et al, Proc. Natl. Acad. Sci. USA (1979) 76:4350-4354. Non-specific antibody binding to the membrane was blocked by pre-incubation with a solution of PBS and 1% nonfat dry milk. Immunological detection of FHA was performed using a 1:1000 dilution of a mixture of (1-54, 1-199, 31E2, 22F10, and 68A6) monoclonal anti-FHA antibodies (obtained from F. Mooi), followed by incubation with a 1:250 dilution of horseradish peroxidase-conjugated goat anti-mouse antisera. HRP activity was detected using a tetramethylbenzidine-containing reaction mixture. fim2 and fim3 production were detected using the same technique and monoclonal antibodies (21E7 and 8E5) specific for these two proteins (obtained from F. Mooi).

Southern Hybridization

B. pertussis chromosomal DNA was isolated, digested with restriction endonucleases, and separated by agarose gel electrophoresis according to standard techniques (Maniatis et al. (1982), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). Transfer of fragments to nitrocellulose followed the method of Smith and Summers (Anal. Biochem. (1980) 109:123-129). Hybridization with probe occurred at 37°C, with 50% formamide and 5xSSC. Membranes were washed twice with 2xSSC at 25°C, twice with 0.1xSSC at 25°C, and then twice with 0.1xSSC at 65°C.

In vitro Bacterial Adherence

B. pertussis strains were grown on plates for two days and then washed twice in phosphate-buffered saline (PBS). 20 μ l of bacterial suspension ($OD_{600}=10$) was added to tissue culture plate wells containing 200 μ l of MEM and a cover slip on which approximately 5×10^4 Chinese Hamster Ovary cells had been innoculated and allowed to grow overnight. After incubation at 37°C, 5%CO₂, for four hours, each well was washed vigorously with PBS three times. Any remaining bacteria and CHO cells were fixed with methanol and then stained with Giemsa. All bacterial strains were studied in duplicate and all experiments repeated at least twice. Bacteria adherent to a single CHO cell were counted visually and the mean with standard deviation determined for each strain. Joint 95% confidence intervals were computed based on central limit theorem approximations and Bonferoni techniques.

Results

Identification and Cloning of the FHA Structural Gene

Previous work had led to the isolation of a
5 cosmid clone, pUW21-26, which hybridized with both vir
and fha DNA probes (Stibitz, et al., 1988, supra). The
analysis of Tn5 insertion mutations within this cosmid,
using FHA colony and Western immunoblots, had suggested
that the FHA structural gene, fhaB, was located on a 10
10 kb EcoRI fragment just to the right of the vir locus.
Furthermore, fhaB transcription was believed to begin
near the left-hand EcoRI site and proceed from left to
right, based upon the correlation of FHA truncated
product size with location of the corresponding Tn5
15 insertion site.

Deletion of the internal 2.4 kb BamHI fragment
of fhaB was performed as described above and the
mutation returned to the B. pertussis chromosome,
yielding strain BP101. The structure of the resultant
20 fhaB mutant locus in this strain was confirmed by
Southern blot analysis. The largest FHA cross-reactive
polypeptide produced by BP101 measures approximately
150 kDa, as determined by Western blot technique. This
truncated FHA product has no hemagglutinating activity.

25 These data confirmed that the structural gene
for FHA must be contained on the 10 kb EcoRI insert of
pDR1. This fragment was, therefore, subcloned for
dideoxy single-stranded DNA sequencing.

30 Construction of fhaB fusion proteins

Seven portions of the fhaB ORF were each
cloned into the expression vector pEX34. The result in
each case was a translational fusion with the first 98
amino acids of the phage MS2 RNA polymerase. Fusion
35 proteins were expressed in an E. coli host and then
purified using preparative SDS-PAGE. One reason for
the construction of these fusion proteins was to

confirm the absence of a translational stop codon in various regions of the ORF. This aim was addressed by comparison of measured fusion protein molecular weights with those theoretically expected from translational read-through of the entire cloned fhaB inserts. Table 1 lists the fusion proteins with the nucleotide coordinates of the respective fhaB inserts: these data confirm the absence of a stop codon in all of these fhaB fragments.

10

<u>Table 1</u>			
	<u>Observed MW</u>	<u>FRAGMENT</u>	
15			
	protein H1	45 Kda	BamHI-RsaI 2836-3786
	protein H2	85 Kda	BamHI-NruI 5212-7294
20	protein H3	77 Kda	PvuII-PvuII 6393-8085
	protein H4	80 Kda	PvuII-BamHI 8085-9922
	protein H5	55 Kda	StuI-BamHI 8752-9922
25	protein H6	32 Kda	EcoRV-BamHI 9462-9922
	protein H7	56 Kda	BamHI-ClaI 9922-11666

30

Western immunoblot analysis using fusion protein antisera

Antisera to each of the seven fusion proteins were prepared by intraperitoneal immunisation of mice and were used for two purposes: to correlate each of the FHA SDS-PAGE bands with a region of the fhaB ORF, and to determine what portions of ORF-encoded poly-

35

peptide are present in whole *Bordetella* sp. extracts. Table 2 shows the results of Western immunoblots using each of the seven fusion protein antisera and an FHA protein gel pattern.

5 The combination of these data with the results of N-terminal amino acid sequencing suggest an origin for the different FHA polypeptide species. The stimulation of a murine polyclonal response by each of the fhaB fusion proteins also argues that FHA contains
10 numerous immunogenic domains.

15

20

25

30

35

-20-

Table 2
Polyclonal Sera

	anti FHA	anti H1	anti H2	anti H3	anti H4	anti H5	anti H6	anti H7
30	---	+	+	-	-	-	-	-
40	---	+	+	-	-	-	-	-
25	---	+	+	+	-	-	-	-
98	---	+	-	-	-	-	-	-
75	---	+	-	-	-	-	-	-
58	---	+	-	-	-	-	-	-

Nucleotide Sequence of the FHA Structural Gene

The sequencing strategy described above yielded a 10036bp-long nucleotide sequence for the EcoRI fragment. Computer analysis identified an open reading frame (ORF) 10789 bp long beginning at an ATG translational start codon 253 bp from the left-hand EcoRI site. Two other in-frame ATG codons are located 45 and 174 bp after the beginning of the ORF; at approximately the position of the third ATG codon begins the use of codons strongly preferred by B. pertussis (defined by B. pertussis pertussis toxin operon codon usage and the UWGCG codon preference program; Gribskov et al., Nucleic Acids Res. (1984) 12:539-549). The ORF and preferred codon usage end at a TAG stop codon 11041 bp from the left-hand EcoRI site. This ORF encompasses the FHA structural gene fhaB; the sequence of the ORF is shown below.

20	GAATTCCTGCGCTGGCACCCGCGGCGGGCCGGGGAGCGGGTTGTCGGCGCA	51
	CGCCTATACGTGCCGGACAGGGTTTGATGGTTTGACTAAGAAATTCCTAC	102
	AAGTCTTGTATAAATATCCATTGATGGACGGGATCATTACTGACTGACGAA	153
25	GTGCTGAGGTTTATCCAGACTATGGCACTGGATTTCAAAACCTAAAACGAG	204
	CAGGCCGATAACGGATTCTGCCGATTACTTCACTTCGCTGGTCGGAATATG	255
	Met	
30	AACACGAACCTGTACAGGCTGGTCTTCAGCCATGTTTCGCGGCATGCTTGTT	306
	AsnThrAsnLeuTyrArgLeuValPheSerHisValArgGlyMetLeuVal	
	CCCGTGAGCGAGCATTGCACCGTCGGAAACACCTTCTGTGGGCGCACGCGT	357
35	ProValSerGluHisCysThrValGlyAsnThrPheCysGlyArgThrArg	
	GGTCAAGCGCGAAGTGGGGCCCGCGCCACGAGCCTGTCCGTAGCGCCCAAT	408
	GlyGlnAlaArgSerGlyAlaArgAlaThrSerLeuSerValAlaProAsn	

	GCGCTGGCCTGGGCCCTGATGTTGGCGTGTACGGGTCTTCCGTTAGTAACG	459
	AlaLeuAlaTrpAlaLeuMetLeuAlaCysThrGlyLeuProLeuValThr	
5	CACGCCCAGGGCTTGGTTCCTCAGGGGCAGACACAGGTGCTGCAGGGCGGG	510
	HisAlaGlnGlyLeuValProGlnGlyGlnThrGlnValLeuGlnGlyGly	
	AACAAGGTTCCCGTTGTCAATATCGCCGACCCAAATTCCGGCGGCGTCTCG	561
	AsnLysValProValValAsnIleAlaAspProAsnSerGlyGlyValSer	
10	CACAACAAGTTCCAGCAGTTCAACGTCGCCAACCCTGGCGTGGTCTTCAAC	612
	HisAsnLysPheGlnGlnPheAsnValAlaAsnProGlyValValPheAsn	
	AACGGCCTGACCGACGGCGTGTCCAGGATCGGCGGGGCGCTGACCAAGAAC	663
15	AsnGlyLeuThrAspGlyValSerArgIleGlyGlyAlaLeuThrLysAsn	
	CCCAACCTGACTCGCCAGGCCTCGGCCATTCTTGCCGAAGTCACGGACACT	714
	ProAsnLeuThrArgGlnAlaSerAlaIleLeuAlaGluValThrAspThr	
	TCGCCCAGTCGCCTGGCCGGTACGCTCGAAGTCTATGGCAAGGGCGCCGAC	765
20	SerProSerArgLeuAlaGlyThrLeuGluValTyrGlyLysGlyAlaAsp	
	CTCATCATCGCCAACCCCAACGGCATCAGCGTCAACGGCCTGAGCACGCTC	816
	LeuIleIleAlaAsnProAsnGlyIleSerValAsnGlyLeuSerThrLeu	
25	AACGCCAGCAACCTGACGCTCACGACGGGGCGTCCCAGCGTCAACGGCGGC	867
	AsnAlaSerAsnLeuThrLeuThrThrGlyArgProSerValAsnGlyGly	
	CGCATCGGCCTTGATGTCCAACAGGGCACCGTCACGATCGAACGAGGCGGC	918
30	ArgIleGlyLeuAspValGlnGlnGlyThrValThrIleGluArgGlyGly	
	GTCAATGCCACCGGCCTGGGCTATTTTCGACGTGGTGGCGCGCCTGGTCAAG	969
	ValAsnAlaThrGlyLeuGlyTyrPheAspValValAlaArgLeuValLys	
35	CTGCAGGGTGCCGTGTGCGAGCAAGCAGGGCAAGCCCCTGGCCGACATCGCG	1020
	LeuGlnGlyAlaValSerSerLysGlnGlyLysProLeuAlaAspIleAla	

	GTGGTCGCCGGCGCCAACCGGTACGACCACGCAACCCGCCGCGCCACGCCG	1071
	ValValAlaGlyAlaAsnArgTyrAspHisAlaThrArgArgAlaThrPro	
5	ATCGCCGCAGGCGCGCGCGGCCGCCGCGGGCGCCTACGCGATTGACGGC	1122
	IleAlaAlaGlyAlaArgGlyAlaAlaAlaGlyAlaTyrAlaIleAspGly	
	ACGGCGGGCGGGCGCCATGTACGGCAAGCACATCACGCTGGTGTCCAGCGAT	1173
	ThrAlaAlaGlyAlaMetTyrGlyLysHisIleThrLeuValSerSerAsp	
10	TCAGGCCTGGGCGTGCGCCAGCTCGGCAGCCTGTCCTCGCCATCGGCCATC	1224
	SerGlyLeuGlyValArgGlnLeuGlySerLeuSerSerProSerAlaIle	
	ACCGTGTCGTCGCGAGGGCGAAATCGCGCTGGGCGACGCCACGGTCCAGCGC	1275
15	ThrValSerSerGlnGlyGluIleAlaLeuGlyAspAlaThrValGlnArg	
	GGCCCGCTCAGCCTCAAGGGCGCGGGGGTTCGTGTCGGCCGGCAAACCTGGCC	1326
	GlyProLeuSerLeuLysGlyAlaGlyValValSerAlaGlyLysLeuAla	
20	TCCGGGGGGGGGGCGGTGAACGTCGCGGGCGGCGGGGCGGTGAAGATCGCG	1377
	SerGlyGlyGlyAlaValAsnValAlaGlyGlyGlyAlaValLysIleAla	
	TCGGCCAGCAGCGTTGGAAACCTCGCGGTGCAAGGCGGCGGCAAGGTACAG	1428
	SerAlaSerSerValGlyAsnLeuAlaValGlnGlyGlyGlyLysValGln	
25	GCCACGCTGTTGAATGCCGGGGGGACGTTGCTGGTGTCTGGGCCGCCAGGCC	1479
	AlaThrLeuLeuAsnAlaGlyGlyThrLeuLeuValSerGlyArgGlnAla	
	GTCCAGCTTGGCGCGGCGAGCAGCCGTCAGGCGCTGTCCGTGAACGCGGGC	1530
30	ValGlnLeuGlyAlaAlaSerSerArgGlnAlaLeuSerValAsnAlaGly	
	GGCGCCCTCAAGGCGGACAAGCTGTCTGGCGACGCGACGGGTCTGACGTGGAT	1581
	GlyAlaLeuLysAlaAspLysLeuSerAlaThrArgArgValAspValAsp	
35	GGCAAGCAGGCCGTCGCGCTGGGGTCTGGCCAGCAGCAATGCGCTGTCTGGTG	1632
	GlyLysGlnAlaValAlaLeuGlySerAlaSerSerAsnAlaLeuSerVal	

	CGTGCCGGCGGGCGCCCTCAAGGCGGGCAAGCTGTCGGCGACGGGGCGACTG	1683
	ArgAlaGlyGlyAlaLeuLysAlaGlyLysLeuSerAlaThrGlyArgLeu	
5	GACGTGGACGGCAAGCAGGCCGTCACGCTGGGTTCGGTTGCGAGCGACGGT	1734
	AspValAspGlyLysGlnAlaValThrLeuGlySerValAlaSerAspGly	
	GCGCTGTCGGTAAGCGCTGGCGGAAACCTGCGGGCGAACGAATTGGTCTCC	1785
	AlaLeuSerValSerAlaGlyGlyAsnLeuArgAlaAsnGluLeuValSer	
10	AGTGCCCAACTTGAGGTGCGTGGGCAGCGGGAGGTCGCGCTGGATGACGCT	1836
	SerAlaGlnLeuGluValArgGlyGlnArgGluValAlaLeuAspAspAla	
	TCGAGCGCACGCGGCATGACCGTGGTTGCCGCAGGAGCGCTGGCGGCCCGC	1887
15	SerSerAlaArgGlyMetThrValValAlaAlaGlyAlaLeuAlaAlaArg	
	AACCTGCAGTCCAAGGGCGCCATCGGCGTACAGGGTGGAGAGGCGGTCAGC	1938
	AsnLeuGlnSerLysGlyAlaIleGlyValGlnGlyGlyGluAlaValSer	
20	GTGGCCAACGCGAACAGCGACGCGGAATTGCGCGTGCGCGGGCGCGGCCAG	1989
	ValAlaAsnAlaAsnSerAspAlaGluLeuArgValArgGlyArgGlyGln	
	GTGGATCTGCACGACCTGAGCGCAGCGCGCGGCGCGGATATCTCCGGCGAG	2040
	ValAspLeuHisAspLeuSerAlaAlaArgGlyAlaAspIleSerGlyGlu	
25	GGGCGCGTCAATATCGGCCGTGCGCGCAGCGATAGCGATGTGAAGGTCTCC	2091
	GlyArgValAsnIleGlyArgAlaArgSerAspSerAspValLysValSer	
	GCGCACGGCGCCTTGTCGATCGATAGCATGACGGCCCTCGGTGCGATCGGC	2142
30	AlaHisGlyAlaLeuSerIleAspSerMetThrAlaLeuGlyAlaIleGly	
	GTCCAGGCAGGCGGCAGCGTGTGCGCCAAGGATATGCGCAGCCGTGGCGCC	2193
	ValGlnAlaGlyGlySerValSerAlaLysAspMetArgSerArgGlyAla	
35	GTCACCGTCAGCGGCGGCGGCCGTCAACCTGGGCGATGTCCAGTCGGAT	2244
	ValThrValSerGlyGlyGlyAlaValAsnLeuGlyAspValGlnSerAsp	

	GGGCAGGTCCGCGCCACCAGCGCGGGCGCCATGACGGTGCGAGACGTCGCG	2295
	GlyGlnValArgAlaThrSerAlaGlyAlaMetThrValArgAspValAla	
5	GCTGCCGCGGACCTTGCGCTGCAGGCGGGCGACGCGTTGCAGGCCGGGTTC	2346
	AlaAlaAlaAspLeuAlaLeuGlnAlaGlyAspAlaLeuGlnAlaGlyPhe	
	CTGAAATCGGCCGGTGCCATGACCGTGAACGGCCGCGATGCCGTGCGACTG	2397
	LeuLysSerAlaGlyAlaMetThrValAsnGlyArgAspAlaValArgLeu	
10	GATGGCGCGCACGCGGGCGGGCAATTGCGGGTTTCCAGCGACGGGCAGGCT	2448
	AspGlyAlaHisAlaGlyGlyGlnLeuArgValSerSerAspGlyGlnAla	
	GCGTTGGGCAGTCTCGCGGCCAAGGGCGAGCTGACGGTATCGGCCGCGCGC	2499
15	AlaLeuGlySerLeuAlaAlaLysGlyGluLeuThrValSerAlaAlaArg	
	GCGGCGACCGTGGCCGAGTTGAAGTCGCTGGACAACATCTCCGTGACGGGC	2550
	AlaAlaThrValAlaGluLeuLysSerLeuAspAsnIleSerValThrGly	
	GGCGAACGCGTGTCGGTTCAGAGCGTCAACAGCGCGTCCAGGGTCGCCATT	2601
20	GlyGluArgValSerValGlnSerValAsnSerAlaSerArgValAlaIle	
	TCGGCGCACGGCGCGCTGGATGTAGGCAAGGTTTCCGCCAAGAGCGGTATC	2652
	SerAlaHisGlyAlaLeuAspValGlyLysValSerAlaLysSerGlyIle	
25	GGGCTCGAAGGCTGGGGCGCGGTCGGAGCGGACTCCCTCGGTCCGACGGC	2703
	GlyLeuGluGlyTrpGlyAlaValGlyAlaAspSerLeuGlySerAspGly	
	GCGATCAGCGTGTCGGGCGCGATGCGGTCAGGGTCGATCAAGCCCGCAGT	2754
30	AlaIleSerValSerGlyArgAspAlaValArgValAspGlnAlaArgSer	
	CTTGCCGACATTTTCGCTGGGGGCGGAAGGCGGCGCCACGCTGGGCGCGGTG	2805
	LeuAlaAspIleSerLeuGlyAlaGluGlyGlyAlaThrLeuGlyAlaVal	
	GAGGCCGCCGGTTCGATCGACGTGCGCGGCGGATCCACGGTGGCGGCGAAC	2856
35	GluAlaAlaGlySerIleAspValArgGlyGlySerThrValAlaAlaAsn	

	TCGCTGCACGCCAATCGCGACGTTCTGGGTCAGCGGCAAGGATGCGGTGCGC	2907
	SerLeuHisAlaAsnArgAspValArgValSerGlyLysAspAlaValArg	
5	GTAACGGCCGCCACCAGCGGGGGCGGTCTGCATGTGTCTGAGCGGCCGCCAG	2958
	ValThrAlaAlaThrSerGlyGlyGlyLeuHisValSerSerGlyArgGln	
	CTCGATCTGGGCGCCGTGCAGGCGCGCGGCGCGCTGGCCCTGGACGGAGGC	3009
	LeuAspLeuGlyAlaValGlnAlaArgGlyAlaLeuAlaLeuAspGlyGly	
10	GCCGGCGTGGCGCTGCAATCGGCCAAGGCTAGCGGCACGCTGCATGTGCAG	3060
	AlaGlyValAlaLeuGlnSerAlaLysAlaSerGlyThrLeuHisValGln	
	GGCGGCGAGCACCTGGACCTGGGCACGTTGGCCGCCGTAGGGGCGGTGGAC	3111
15	GlyGlyGluHisLeuAspLeuGlyThrLeuAlaAlaValGlyAlaValAsp	
	GTCAATGGCACGGGAGACGTGCGCGTTGCGAAGCTGGTGAGCGATGCAGGC	3162
	ValAsnGlyThrGlyAspValArgValAlaLysLeuValSerAspAlaGly	
20	GCCGATCTGCAAGCGGGGCGCTCCATGACGCTGGGTATCGTCGACACGACC	3213
	AlaAspLeuGlnAlaGlyArgSerMetThrLeuGlyIleValAspThrThr	
	GGCGATCTGCAGGCGCGCGCGCAGCAGAAGCTGGAGCTCGGGTCGGTTAAG	3264
	GlyAspLeuGlnAlaArgAlaGlnGlnLysLeuGluLeuGlySerValLys	
25	AGCGATGGCGGCCTTCAGGCGGCCGCCGGCGGGGCCCTCAGCCTGGCGGCG	3315
	SerAspGlyGlyLeuGlnAlaAlaAlaGlyGlyAlaLeuSerLeuAlaAla	
	GCGGAAGTCGCAGGGGCGCTGGAGCTCTCGGGCCAGGGCGTCACCGTGGAC	3366
30	AlaGluValAlaGlyAlaLeuGluLeuSerGlyGlnGlyValThrValAsp	
	AGAGCCAGCGCTAGCCGGGCACGCATCGACAGCACCGGTTCTGGTCGGCATC	3417
	ArgAlaSerAlaSerArgAlaArgIleAspSerThrGlySerValGlyIle	
35	GGCGCGCTGAAGGCAGGCGCTGTCTGAGGCCGCTCGCCACGGCGGGCGCGC	3468
	GlyAlaLeuLysAlaGlyAlaValGluAlaAlaSerProArgArgAlaArg	

CGCGCGCTGCGGCAGGATTTCTTCACGCCCCGGCAGCGTGGTGGTCCGCGCC 3519
ArgAlaLeuArgGlnAspPhePheThrProGlySerValValValArgAla

5 CAGGGCAATGTCACGGTCGGGCGCGGCGATCCGCATCAGGGCGTGCTGGCC 3570
GlnGlyAsnValThrValGlyArgGlyAspProHisGlnGlyValLeuAla

CAGGGCGACATCATCATGGATGCGAAGGGCGGCACCTTGCTGTTGCGCAAC 3621
GlnGlyAspIleIleMetAspAlaLysGlyGlyThrLeuLeuLeuArgAsn

10 GATGCCTTGACCGAGAACGGGACGGTCACCATATCGGCCGATTCGGCCGTG 3672
AspAlaLeuThrGluAsnGlyThrValThrIleSerAlaAspSerAlaVal

CTCGAGCATTCACCATCGAGAGCAAGATCAGCCAGAGCGTGCTGGCTGCC 3723
15 LeuGluHisSerThrIleGluSerLysIleSerGlnSerValLeuAlaAla

AAAGGGGACAAGGGCAAGCCGGCGGTGTCGGTGAAGGTCGCGAAGAAGCTG 3774
LysGlyAspLysGlyLysProAlaValSerValLysValAlaLysLysLeu

20 TTTCTCAATGGTACGTTGCGGGCCGTCAACGACAACAACGAAACCATGTCC 3825
PheLeuAsnGlyThrLeuArgAlaValAsnAspAsnAsnGluThrMetSer

GGGCGCCAGATCGACGTCGTGGACGGACGTCCGCAGATCACCGACGCGGTC 3876
GlyArgGlnIleAspValValAspGlyArgProGlnIleThrAspAlaVal

25 ACGGGCGAAGCGCGTAAGGACGAATCGGTTGTGTCCGACGCCGCGCTCGTG 3927
ThrGlyGluAlaArgLysAspGluSerValValSerAspAlaAlaLeuVal

GCCGATGGCGGTCCGATCGTGGTCGAGGCCGGCGAGCTGGTCAGCCATGCC 3978
30 AlaAspGlyGlyProIleValValGluAlaGlyGluLeuValSerHisAla

GGCGGTATCGGCAACGGCCGCAACAAGGAGAATGGCGCCAGCGTCACCGTG 4029
GlyGlyIleGlyAsnGlyArgAsnLysGluAsnGlyAlaSerValThrVal

35 CGCACGACTGGCAACCTGGTCAACAAGGGCTACATCTCGGCCGGAAGCAG 4080
ArgThrThrGlyAsnLeuValAsnLysGlyTyrIleSerAlaGlyLysGln

	GGCGTGCTCGAGGTGGGCGGCGCCTTGACGAACGAGTTCCTGGTCGGCTCG	4131
	GlyValLeuGluValGlyGlyAlaLeuThrAsnGluPheLeuValGlySer	
5	GACGGCACCCAGCGCATCGAGGCGCAGCGCATCGAGAACAGGGGCACCTTC	4182
	AspGlyThrGlnArgIleGluAlaGlnArgIleGluAsnArgGlyThrPhe	
	CAGAGCCAGGCTCCGGCGGGCACGGCCGGCGCCCTGGTGGTCAAGGCTGCC	4233
	GlnSerGlnAlaProAlaGlyThrAlaGlyAlaLeuValValLysAlaAla	
10	GAGGCCATCGTGACGACGGCGTCATGGCCACCAAAGGCGAGATGCAGATC	4284
	GluAlaIleValHisAspGlyValMetAlaThrLysGlyGluMetGlnIle	
	GCCGGCAAGGGCGGCGGGTCTCCGACCGTCACCGCCGGCGCAAAGGCGACG	4335
15	AlaGlyLysGlyGlyGlySerProThrValThrAlaGlyAlaLysAlaThr	
	ACCAGCGCGAACAAGCTGAGCGTCGACGTGGCAAGCTGGGACAACGCGGGA	4386
	ThrSerAlaAsnLysLeuSerValAspValAlaSerTrpAspAsnAlaGly	
20	AGCCTGGATATCAAGAAGGGCGGCGCGCAGGTCACGGTGGCCGGGCGCTAT	4437
	SerLeuAspIleLysLysGlyGlyAlaGlnValThrValAlaGlyArgTyr	
	GCCGAGCACGGCGAGGTTTCGATACAGGGCGATTACACCGTCTCGGCCGAC	4488
	AlaGluHisGlyGluValSerIleGlnGlyAspTyrThrValSerAlaAsp	
25	GCCATCGCGCTGGCGGCGCAGGTCACCCAGCGCGGAGGCGCCGCGAACCTG	4539
	AlaIleAlaLeuAlaAlaGlnValThrGlnArgGlyGlyAlaAlaAsnLeu	
	ACCTCGCGGCACGACACCCGTTTCTCCAACAAGATTCGCCTGATGGGGCCG	4590
30	ThrSerArgHisAspThrArgPheSerAsnLysIleArgLeuMetGlyPro	
	TTGCAGGTCAACGCCGGCGGGCCGGTGTCCAATACCGGCAATCTGAAAGTG	4641
	LeuGlnValAsnAlaGlyGlyProValSerAsnThrGlyAsnLeuLysVal	
35	CGCGAGGGCGTGACCGTAACGGCGGCGTCGTTTCGACAACGAGACCGGGGCC	4692
	ArgGluGlyValThrValThrAlaAlaSerPheAspAsnGluThrGlyAla	

	GAGGTCATGGCCAAGAGCGCCACGCTGACGACTTCCGGGGCCGCGCGCAAC	4743
	GluValMetAlaLysSerAlaThrLeuThrThrSerGlyAlaAlaArgAsn	
	GCGGGCAAGATGCAGGTCAAGGAGGCCGCCACGATCGTTGCCGCCAGCGTT	4794
5	AlaGlyLysMetGlnValLysGluAlaAlaThrIleValAlaAlaSerVal	
	TCCAATCCCGGCACGTTACGCGCCGGCAAGGATATCACTGTTACCTCGCGC	4845
	SerAsnProGlyThrPheThrAlaGlyLysAspIleThrValThrSerArg	
10	GGAGGATTCGATAACGAAGGCAAGATGGAGTCCAACAAGGACATCGTCATC	4896
	GlyGlyPheAspAsnGluGlyLysMetGluSerAsnLysAspIleValIle	
	AAGACGGAACAGTTCAGCAATGGCAGGGTTCTCGACGCCAAGCATGATCTG	4947
15	LysThrGluGlnPheSerAsnGlyArgValLeuAspAlaLysHisAspLeu	
	ACGGTCACGGCGAGCGGGCAGGCGGACAACCGGGGCAGCCTGAAGGCAGGC	4998
	ThrValThrAlaSerGlyGlnAlaAspAsnArgGlySerLeuLysAlaGly	
	CACGATTTACGGTGCAGGCCCAGCGTATCGACAATAGCGGAACCATGGCC	5049
20	HisAspPheThrValGlnAlaGlnArgIleAspAsnSerGlyThrMetAla	
	GCCGGCCACGACGCCACGCTGAAGGCGCCGACCTGCGCAATACGGGGCCAG	5100
	AlaGlyHisAspAlaThrLeuLysAlaProHisLeuArgAsnThrGlyGln	
25	GTCGTAGCCGGGCACGACATCCATATCATCAACAGCGCCAAGCTGGAGAAC	5151
	ValValAlaGlyHisAspIleHisIleIleAsnSerAlaLysLeuGluAsn	
	ACCGGGCGCGTGGATGCGCGCAACGACATCGCTCTGGATGTGGCGGATTTT	5202
30	ThrGlyArgValAspAlaArgAsnAspIleAlaLeuAspValAlaAspPhe	
	ACCAACACGGGATCCCTCTACGCCGAGCATGACGCGACGCTGACGCTTGCG	5253
	ThrAsnThrGlySerLeuTyrAlaGluHisAspAlaThrLeuThrLeuAla	
35	CAAGGCACGCAGCGCGATCTGGTGGTGGACCAGGATCATATCCTGCCGGTG	5304
	GlnGlyThrGlnArgAspLeuValValAspGlnAspHisIleLeuProVal	

	GCGGAGGGGACGTTACGCGTCAAGGCCAAGTCGCTGACCACCGAAATCGAG	5355
	AlaGluGlyThrLeuArgValLysAlaLysSerLeuThrThrGluIleGlu	
5	ACCGGCAATCCCGGCAGCCTGATCGCCGAGGTGCAGGAAAATATCGACAAC	5406
	ThrGlyAsnProGlySerLeuIleAlaGluValGlnGluAsnIleAspAsn	
	AAGCAGGCCATCGTCGTCGGCAAGGACCTGACGCTGAGTTCGGCGCACGGC	5457
	LysGlnAlaIleValValGlyLysAspLeuThrLeuSerSerAlaHisGly	
10	AACGTGGCCAACGAAGCGAACGCGCTGCTGTGGGCCCGCCGGGGAGCTGACC	5508
	AsnValAlaAsnGluAlaAsnAlaLeuLeuTrpAlaAlaGlyGluLeuThr	
	GTCAAGGCGCAGAACATCACCAATAAACGGGCCGCGCTGATCGAGGCGGGC	5559
15	ValLysAlaGlnAsnIleThrAsnLysArgAlaAlaLeuIleGluAlaGly	
	GCCAACGCCCCGGCTGACGGCGGCCGTTGCCTTGCTCAACAAGCTGGGCCGC	5610
	GlyAsnAlaArgLeuThrAlaAlaValAlaLeuLeuAsnLysLeuGlyArg	
	ATTCGCGCGGGCGAGGACATGCACCTGGATGCGCCGCGCATCGAGAACACC	5661
20	IleArgAlaGlyGluAspMetHisLeuAspAlaProArgIleGluAsnThr	
	GCGAAACTGAGCGGCGAGGTGCAACGCAAAGGCGTGCAAGGACGTCGGGGGA	5712
	AlaLysLeuSerGlyGluValGlnArgLysGlyValGlnAspValGlyGly	
25	GGCGAGCACGGCCGCTGGAGCGGTATCGGCTATGTCAACTACTGGTTGCGC	5763
	GlyGluHisGlyArgTrpSerGlyIleGlyTyrValAsnTyrTrpLeuArg	
	GCCGGCAATGGGAAGAAGGCGGGAACCATCGCCGCGCCGTGGTATGGCGGT	5814
30	AlaGlyAsnGlyLysLysAlaGlyThrIleAlaAlaProTrpTyrGlyGly	
	GATCTGACGGCGGAGCAGTCGCTCATCGAGGTCGGCAAGGATCTCTATCTG	5865
	AspLeuThrAlaGluGlnSerLeuIleGluValGlyLysAspLeuTyrLeu	
	AATGCCGGAGCGCGCAAGGACGAACATCGCCATCTGCTCAATGAAGGCGTG	5916
35	AsnAlaGlyAlaArgLysAspGluHisArgHisLeuLeuAsnGluGlyVal	

ATCCAGGCGGGCGGCCATGGCCACATCGGCGGCGACGTGGACAACCGGTCTG 5967
IleGlnAlaGlyGlyHisGlyHisIleGlyGlyAspValAspAsnArgSer

GTGGTGCGCACCGTGTCCGCCATGGAGTATTTCAAGACGCCTCTTCCGGTG 6018
5 ValValArgThrValSerAlaMetGluTyrPheLysThrProLeuProVal

AGCCTGACTGCCCTGGACAATCGTGCCGGCTTGTCTCCGGCGACCTGGAAC 6069
SerLeuThrAlaLeuAspAsnArgAlaGlyLeuSerProAlaThrTrpAsn

TTCCAGTCCACGTATGAACTCCTGGATTATCTGCTGGACCAGAATCGCTAC 6120
10 PheGlnSerThrTyrGluLeuLeuAspTyrLeuLeuAspGlnAsnArgTyr

GAGTACATTTGGGGGCTGTATCCGACCTACACCGAATGGTCGGTGAATACG 6171
GluTyrIleTrpGlyLeuTyrProThrTyrThrGluTrpSerValAsnThr
15

CTGAAGAACCTCGACCTGGGCTACCAGGCCAAGCCGGCTCCCACTGCGCCG 6222
LeuLysAsnLeuAspLeuGlyTyrGlnAlaLysProAlaProThrAlaPro

CCGATGCCCAAGGCTCCCGAACTCGACCTGCGTGGCCATACGCTGGAGTCG 6273
20 ProMetProLysAlaProGluLeuAspLeuArgGlyHisThrLeuGluSer

GCCGAAGGCCGGAAGATCTTTGGCGAGTACAAGAAGCTGCAAGGCGAGTAC 6324
AlaGluGlyArgLysIlePheGlyGluTyrLysLysLeuGlnGlyGluTyr

GAGAAGGCCGAAGATGGCCGTCCAGGCCGTGGAGGCTTACGGCGAGGCTACT 6375
25 GluLysAlaLysMetAlaValGlnAlaValGluAlaTyrGlyGluAlaThr

CGGCGCGTCCATGATCAGCTGGGCCAACGTTATGGTAAGGCCCTGGGCGGC 6426
ArgArgValHisAspGlnLeuGlyGlnArgTyrGlyLysAlaLeuGlyGly
30

ATGGATGCCGAGACCAAGGAGGTGACGGCATCATCCAGGAGTTCGCCGCG 6477
MetAspAlaGluThrLysGluValAspGlyIleIleGlnGluPheAlaAla

GATCTGCGAACGGTCTATGCGAAGCAGGCCGACCAGGCGACCATCGACGCA 6528
35 AspLeuArgThrValTyrAlaLysGlnAlaAspGlnAlaThrIleAspAla

	GAGACGGACAAGGTCGCCCAGCGCTACAAGTCGCAGATCGACGCGGTGCGG	6579
	GluThrAspLysValAlaGlnArgTyrLysSerGlnIleAspAlaValArg	
5	CTGCAGGCGATCCAGCCTGGCCGGGTCACGCTGGCCAAGGCGCTGTCGGCG	6630
	LeuGlnAlaIleGlnProGlyArgValThrLeuAlaLysAlaLeuSerAla	
	GCGCTGGGCGCCGACTGGCGCGCGCTGGGTCACTCCCAATTGATGCAGCGC	6681
	AlaLeuGlyAlaAspTrpArgAlaLeuGlyHisSerGlnLeuMetGlnArg	
10	TGGAAGGATTTCAAGGCGGGCAAGCGCGGCGCGGAAATCGCGTTCTATCCC	6732
	TrpLysAspPheLysAlaGlyLysArgGlyAlaGluIleAlaPheTyrPro	
	AAGGAACAAACCGTGCTGGCCGCCGGCGCCGTTTGACCCTGTCCAACGGG	6783
15	LysGluGlnThrValLeuAlaAlaGlyAlaGlyLeuThrLeuSerAsnGly	
	GCGATCCACAACGGCGAGAACGCCGCGCAGAATCGCGGCCGCGCGGAAGGC	6834
	AlaIleHisAsnGlyGluAsnAlaAlaGlnAsnArgGlyArgProGluGly	
	CTGAAAATCGGCGCACATTCGGCGACTTCGGTGAGCGGCTCGTTTCGACGCC	6885
20	LeuLysIleGlyAlaHisSerAlaThrSerValSerGlySerPheAspAla	
	TTGCGCGACGTGGGGCTGGAAAAGCGGCTGGATATCGACGATGCGCTGGCT	6936
	LeuArgAspValGlyLeuGluLysArgLeuAspIleAspAspAlaLeuAla	
25	GCCGTGCTCGTGAATCCGCATATTTTCACGCGGATCGGGGCGGCTCAGACA	6987
	AlaValLeuValAsnProHisIlePheThrArgIleGlyAlaAlaGlnThr	
	TCCCTTGCCGACGGCGCCGCGGGCCGGCGCTGGCGCGCCAGGCCAGGCAA	7038
30	SerLeuAlaAspGlyAlaAlaGlyProAlaLeuAlaArgGlnAlaArgGln	
	GCGCCGGAGACCGACGGCATGGTGGATGCGCGAGGGCTGGGCAGCGCCGAT	7089
	AlaProGluThrAspGlyMetValAspAlaArgGlyLeuGlySerAlaAsp	
	GCGCTCGCTTCCCTGGCCAGCTTGGACGCGGCGCAAGGGCTGGAGGTATCC	7140
35	AlaLeuAlaSerLeuAlaSerLeuAspAlaAlaGlnGlyLeuGluValSer	

GGCAGGCGCAATGCGCAGGTGGCCGACGCCGGGCTCGCCGGGCCGAGCGCC 7191
GlyArgArgAsnAlaGlnValAlaAspAlaGlyLeuAlaGlyProSerAla

5 GTCGCGGCGCCGGCCGTCGGGGCGGCCGATGTCGGCGTGGAGCCTGTCACG 7242
ValAlaAlaProAlaValGlyAlaAlaAspValGlyValGluProValThr

GGGGACCAGGTCGACCAGCCTGTCGTGGCGGTCTGGGCTCGAGCAGCCTGTC 7293
GlyAspGlnValAspGlnProValValAlaValGlyLeuGluGlnProVal

10 GCGACGGTCCGGGTCGCGCCGCCAGCCGTGCGGTTGCCGCGGCCGCTGTTC 7344
AlaThrValArgValAlaProProAlaValAlaLeuProArgProLeuPhe

GAAACCCGCATCAAGTTTATCGACCAGAGCAAATTCTACGGCTCGCGTTAT 7395
15 GluThrArgIleLysPheIleAspGlnSerLysPheTyrGlySerArgTyr

TTCTTCGAGCAGATCGGCTACAAGCCCGATCGCGCCGCGCGGGTGGCGGGC 7446
PhePheGluGlnIleGlyTyrLysProAspArgAlaAlaArgValAlaGly

GACAACTATTTGATACACGCTGGTGCGCGAGCAGGTGCGGCGCGCCCTG 7497
20 AspAsnTyrPheAspThrThrLeuValArgGluGlnValArgArgAlaLeu

GGCGGCTATGAAAGCCGCCTGCCCCGTGCGCGGTGTCGCGTTGGTGGCCAAG 7548
GlyGlyTyrGluSerArgLeuProValArgGlyValAlaLeuValAlaLys

25 CTGATGGATTCTGGCCGGGACGGTCGGCAAGGCGCTGGGCCTGAAGGTGGGT 7599
LeuMetAspSerAlaGlyThrValGlyLysAlaLeuGlyLeuLysValGly

GTCGCGCCGACCGCGCAGCAGCTCAAGCAGGCCGACCGCGATTTCGTCTGG 7650
ValAlaProThrAlaGlnGlnLeuLysGlnAlaAspArgAspPheValTrp

30 TACGTGGATACCGTGATCGACGGCCAGAAGGTTCTCGCTCCCCGGCTGTAC 7701
TyrValAspThrValIleAspGlyGlnLysValLeuAlaProArgLeuTyr

CTGACCGAGGCGACGCGCCAGGGCATCACGGATCAGTACGCCGGCGGCGGG 7752
35 LeuThrGluAlaThrArgGlnGlyIleThrAspGlnTyrAlaGlyGlyGly

	GCGCTGATTGCCTCCGGCGGGCGACGTAACGTCAATACGGACGGCCATGAC	7803
	AlaLeuIleAlaSerGlyGlyAspValThrValAsnThrAspGlyHisAsp	
5	GTCAGTTCGGTCAACGGGCTGATCCAGGGCAGGAGCGTCAAGGTGGACGCG	7854
	ValSerSerValAsnGlyLeuIleGlnGlyArgSerValLysValAspAla	
	GGCAAGGGCAAGGTCGTGGTGGCCGACAGCAAGGGGGCGGGCGGCGGCATC	7905
	GlyLysGlyLysValValValAlaAspSerLysGlyAlaGlyGlyGlyIle	
10	GAGGCCGATGACGAGGTCTGACGTCTCAGGCCGGGATATCGGCATCGAGGGC	7956
	GluAlaAspAspGluValAspValSerGlyArgAspIleGlyIleGluGly	
	GGCAAGCTGCGCGGCAAGGATGTCAGGCTCAAGGCCGACACGGTCAAGGTC	8007
15	GlyLysLeuArgGlyLysAspValArgLeuLysAlaAspThrValLysVal	
	GCGACCTCGATGCGTTACGACGACAAGGGCAGGCTGGCGGCGCGCGGCGAC	8058
	AlaThrSerMetArgTyrAspAspLysGlyArgLeuAlaAlaArgGlyAsp	
20	GGCGCCCTGGATGCGCAAGGCGGCCAGCTGCATATCGAGGCCAAGCGCCTG	8109
	GlyAlaLeuAspAlaGlnGlyGlyGlnLeuHisIleGluAlaLysArgLeu	
	GAGACGGCCGGCGCGACGCTCAAGGGCGGCAAGGTGAAGCTGGATGTCTGAT	8160
	GluThrAlaGlyAlaThrLeuLysGlyGlyLysValLysLeuAspValAsp	
25	GACGTCAAGTTGGGCGGCGTGTACGAGGCGGGGTCCAGCTACGAGAACAAG	8211
	AspValLysLeuGlyGlyValTyrGluAlaGlySerSerTyrGluAsnLys	
	AGCTCGACGCCGCTGGGCAGCCTGTTCGCCATCCTGTCGTCGACGACGGAA	8262
30	SerSerThrProLeuGlySerLeuPheAlaIleLeuSerSerThrThrGlu	
	ACCAACCAGTCGGCACACGCGAACCATTACGGTACGCGCATCGAAGCCGGT	8313
	ThrAsnGlnSerAlaHisAlaAsnHisTyrGlyThrArgIleGluAlaGly	
35	ACGCTGGAAGGAAAGATGCAGAACCTGGAGATCGAAGGCGGTTCGGTCGAT	8364
	ThrLeuGluGlyLysMetGlnAsnLeuGluIleGluGlyGlySerValAsp	

GCCGCGCATACGGACCTGTCCGTGGCCCGCGACGCGAGGTTCAAGGCCGCC 8415
AlaAlaHisThrAspLeuSerValAlaArgAspAlaArgPheLysAlaAla

5 GCGGATTTTCGCGCACGCCGAGCATGAGAAGGATGTGCGCCAACTGTCCCTG 8466
AlaAspPheAlaHisAlaGluHisGluLysAspValArgGlnLeuSerLeu

GGTGCCAAGGTGGGGGCGGGCGGCTACGAGGCGGGCTTCAGCCTGGGCAGC 8517
GlyAlaLysValGlyAlaGlyGlyTyrGluAlaGlyPheSerLeuGlySer

10 GAAAGCGGTCTGGAAGCGCACGCCGCGCGGTATGACCGCGGGCGCTGAA 8568
GluSerGlyLeuGluAlaHisAlaGlyArgGlyMetThrAlaGlyAlaGlu

GTCAAGGTAGGTTATCGGGCATCGCACGAACAGTCCTCGGAAACCGAAAAG 8619
ValLysValGlyTyrArgAlaSerHisGluGlnSerSerGluThrGluLys

15 TCCTATCGCAACGCGAACCTCAATTTCCGGTGGAGGCTCCGTCGAGGCTGGC 8670
SerTyrArgAsnAlaAsnLeuAsnPheGlyGlyGlySerValGluAlaGly

AATGTCCTGGATATCGGCGGCGCCGACATCAACCGGAACCGGTACGGCGGC 8721
20 AsnValLeuAspIleGlyGlyAlaAspIleAsnArgAsnArgTyrGlyGly

GCCGCGAAGGGGAACGCCGGGACCGAGGAGGCCTTGCGCATGCGCGCCAAG 8772
AlaAlaLysGlyAsnAlaGlyThrGluGluAlaLeuArgMetArgAlaLys

25 AAGGTCGAGTCCACCAAGTACGTCAGCGAGCAGACGAGCCAGAGCTCCGGC 8823
LysValGluSerThrLysTyrValSerGluGlnThrSerGlnSerSerGly

TGGAGCGTGGAGGTGGCATCGACGGCCAGTGCCCGTTCCAGCCTGCTGACG 8874
TrpSerValGluValAlaSerThrAlaSerAlaArgSerSerLeuLeuThr

30 GCCGCCACGCGCCTGGGCGACAGCGTGGCGCAGAATGTCGAGGACGGCCGC 8925
AlaAlaThrArgLeuGlyAspSerValAlaGlnAsnValGluAspGlyArg

GAGATCCGCGGCGAGCTGATGGCTGCGCAAGTCGCCGCGGAGGCCACGCAA 8976
35 GluIleArgGlyGluLeuMetAlaAlaGlnValAlaAlaGluAlaThrGln

	CTGGTAACCGCCGACACGGCGGCGGTGGCACTGAGTGCCGGAATCAGCGCC	9027
	LeuValThrAlaAspThrAlaAlaValAlaLeuSerAlaGlyIleSerAla	
5	GACTTCGACAGCAGCCACAGCCGCTCCACCTCGCAGAATACCCAATATCTG	9078
	AspPheAspSerSerHisSerArgSerThrSerGlnAsnThrGlnTyrLeu	
	GGCGGAAACTTGTCCATCGAGGCCACCGAGGGCGATGCGACGCTGGTGGGC	9129
	GlyGlyAsnLeuSerIleGluAlaThrGluGlyAspAlaThrLeuValGly	
10	GCGAAGTTCGGCGGTGGCGACCAGGTCAGCTTGAAGGCAGCGAAGAGCGTG	9180
	AlaLysPheGlyGlyGlyAspGlnValSerLeuLysAlaAlaLysSerVal	
	AACCTCATGGCGGCCGAATCGACCTTCGAATCGTACTCGGAGAGCCACAAC	9231
15	AsnLeuMetAlaAlaGluSerThrPheGluSerTyrSerGluSerHisAsn	
	TTCCACGCCTCCGCGACGCGAACCTTGGCGCCAACGCCGTGCAGGGCGCC	9282
	PheHisAlaSerAlaAspAlaAsnLeuGlyAlaAsnAlaValGlnGlyAla	
	GTTGGCCTGGGGTTGACTGCGGGTATGGGGACGTCGCATCAGATTACCAAC	9333
20	ValGlyLeuGlyLeuThrAlaGlyMetGlyThrSerHisGlnIleThrAsn	
	GAAACCGGCAAGACCTATGCCGGAACCTCGGTGGATGCGGCGAACGTGTCG	9384
	GluThrGlyLysThrTyrAlaGlyThrSerValAspAlaAlaAsnValSer	
25	ATCGATGCAGGCAAGGATCTGAACCTTTCGGGTCCCGCGTGCGGGGTAAG	9435
	IleAspAlaGlyLysAspLeuAsnLeuSerGlySerArgValArgGlyLys	
	CATGTTGTCCTGGATGTCGAGGGCGATATCAATGCGACCAGCAAGCAGGAT	9486
30	HisValValLeuAspValGluGlyAspIleAsnAlaThrSerLysGlnAsp	
	GAACGCAACTACAACCTCCAGCGGTGGCGGTGGGACGCCTCGGCAGGGGTG	9537
	GluArgAsnTyrAsnSerSerGlyGlyGlyTrpAspAlaSerAlaGlyVal	
	GCGATTCAGAACCGCACGTTGGTTGCGCCCGTGGGGTCTGCCGGCTTCAAT	9588
35	AlaIleGlnAsnArgThrLeuValAlaProValGlySerAlaGlyPheAsn	

	TTCAATACGGAACACGACAATTCGCGCCTGACCAATGACGGGGCGGCGGGT	9639
	PheAsnThrGluHisAspAsnSerArgLeuThrAsnAspGlyAlaAlaGly	
5	GTCGTTGCCAGCGACGGGTTGACGGGCCATGTGAAAGGCGACGCCAACCTG	9690
	ValValAlaSerAspGlyLeuThrGlyHisValLysGlyAspAlaAsnLeu	
	ACCGGCGCGACCATTGCCGATTTGTCGGGCAAGGGCAATCTCAAGGTCGAC	9741
	ThrGlyAlaThrIleAlaAspLeuSerGlyLysGlyAsnLeuLysValAsp	
10	GGCGCGGTCAACGCGCAGAACCTGAAAGACTACCGCGACAAGGACGGCGGC	9792
	GlyAlaValAsnAlaGlnAsnLeuLysAspTyrArgAspLysAspGlyGly	
	AGCGGCGGCCTGAACGTGGGCATCTCGTCGACCACGCTGGCGCCCACCGTG	9843
15	SerGlyGlyLeuAsnValGlyIleSerSerThrThrLeuAlaProThrVal	
	GGCGTGGCGTTTCGGCAGGGTGGCCGGAGAGGATTATCAGGCCGAGCAGCGC	9894
	GlyValAlaPheGlyArgValAlaGlyGluAspTyrGlnAlaGluGlnArg	
	GCCACGATTGACGTGGTCAAACCAAGGATCCCGCGCGCCTGCAGGTGGGC	9945
20	AlaThrIleAspValGlyGlnThrLysAspProAlaArgLeuGlnValGly	
	GGCGGCGTCAAGGGTACCCTCAATCAGGACGCCGCGCAGGCCACGGTCGTT	9996
	GlyGlyValLysGlyThrLeuAsnGlnAspAlaAlaGlnAlaThrValVal	
25	CAGCGCAACAAGCACTGGGCCGGAGGCGGGTCGGAATTCTCGGTGGCTGGC	10047
	GlnArgAsnLysHisTrpAlaGlyGlyGlySerGluPheSerValAlaGly	
	AAGTCACTGAAGAAGAAGAACCAGGTCCGCCCGGTGGAGACGCCGACGCCG	10098
30	LysSerLeuLysLysLysAsnGlnValArgProValGluThrProThrPro	
	GATGTCGTGGATGGACCGCCTAGCCGTCCACCACGCCGCCCGCGTCGCCG	10149
	AspValValAspGlyProProSerArgProThrThrProProAlaSerPro	
35	CAGCCGATCCGCGCGACGGTCGAGGTCAGTTCGCCGCCCGCGGTGTCCGTG	10200
	GlnProIleArgAlaThrValGluValSerSerProProProValSerVal	

	GCCACGGTCGAAGTCGTGCCGCGGCCGAAGGTCGAAACCGGCTCAGCCGCT	10251
	AlaThrValGluValValProArgProLysValGluThrGlySerAlaAla	
5	TCCGCCTCGGCCGGTGGCGCCCAGGTCGTGCCGGTGACGCCTCCCAAGGTG	10302
	SerAlaSerAlaGlyGlyAlaGlnValValProValThrProProLysVal	
	GAGGTCGCCAAGGTGGAGGTCGCCAAGGTGGAAGTCGTGCCGCGGCCGAAG	10353
	GluValAlaLysValGluValAlaLysValGluValValProArgProLys	
10	GTTGAAACGGCTCAGCCGCTTCCGCCCCGGCCGGTGGTGGCCGAGAAGGTG	10404
	ValGluThrAlaGlnProLeuProProArgProValValAlaGluLysVal	
	ACGACGCCGGCGGTCCAGCCCCAGCTTGCCAAGGTGGAGACGGTGCAGCCG	10455
15	ThrThrProAlaValGlnProGlnLeuAlaLysValGluThrValGlnPro	
	GTGAAGCCCCGAAACCACCAAGCCGTTGCCCAAGCCGCTGCCGGTGGCGAAG	10506
	ValLysProGluThrThrLysProLeuProLysProLeuProValAlaLys	
20	GTGACGAAAGCGCCGCCCGGTTGTGGAGACCGCCAGCCGCTGCCGCCG	10557
	ValThrLysAlaProProProValValGluThrAlaGlnProLeuProPro	
	GTCAAGCCACAGAAGGCGACCCCCGGCCCCGTGGCTGAGGTGGGCAAGGCT	10608
	ValLysProGlnLysAlaThrProGlyProValAlaGluValGlyLysAla	
25	ACGGTCACGACGGTGCAGGTGCAGAGTGCGCCGCCCAAGCCGGCCCCGGTG	10659
	ThrValThrThrValGlnValGlnSerAlaProProLysProAlaProVal	
	GCCAAGCAGCCCGCGCCTGCACCGAAGCCCAAGCCCAAGCCCAAGCCCAAG	10710
30	AlaLysGlnProAlaProAlaProLysProLysProLysProLysProLys	
	GCCGAGCGTCCGAAGCCGGGCAAACGACGCCCTTGAGCGGGCGCCACGTG	10761
	AlaGluArgProLysProGlyLysThrThrProLeuSerGlyArgHisVal	
35	GTGCAACAGCAGGTGCAGGTCTTGCAGCGGCAAGCGAGTGACATCAACAAC	10812
	ValGlnGlnGlnValGlnValLeuGlnArgGlnAlaSerAspIleAsnAsn	

	ACCAAGAGCCTGCCTGGCGGGAAGCTGCCCAAGCCGGTCACCGTGAAGCTG	10863
	ThrLysSerLeuProGlyGlyLysLeuProLysProValThrValLysLeu	
5	ACCGACGAGAACGGCAAGCCGCAGACGTATACGATCAACCGGCGCGAGGAT	10914
	ThrAspGluAsnGlyLysProGlnThrTyrThrIleAsnArgArgGluAsp	
	CTGATGAAGCTCAACGGCAAGGTGCTGTCCACCAAGACGACACTGGGCCTG	10965
	LeuMetLysLeuAsnGlyLysValLeuSerThrLysThrThrLeuGlyLeu	
10	GAGCAGACCTTCCGCCTGCGGTCGAGGATATCGGCGGCAAGAACTACCGGG	11016
	GluGlnThrPheArgLeuArgSerArgIleSerAlaAlaArgThrThrGly	
	TCTTCTATGAAACCAACAAATAGGTAGTCGCGGCCTGCCGCGGCTCGGCGC	11067
15	SerSerMetLysProThrAsnArg	
	ATGGGGATTTCGCAGGGTTCTCATGCGCCGGCCAATGCCGGATAGCGGTGCA	11118
	ATTGCCGACCATTTTCGCGCACCGCGCTCAAGGACGTAGGGTCGACGGCAGG	11169
20	CGGGACAGTTTTTTGACGTGAAACTGACCGAGTGTCCGCAGGCATTGAATGG	11220
	TCAGCAAGTGGGATTGTTCTTCGAATCTGGTGGCACGGTTGACTATACGTC	11271
	GGGAAACCTGTTTGCGTATCGGGCCGATAGTCAGGGCGTCGAACAGGCTAC	11322
25	CGCAGAGCGAAAGCCGACAACGTGCAAGCCAATCTGGATGGTTCCGCTATT	11373
	CATTTGGGCCGCAACAAGGGTGCGCAGGCTGCTCAGACGTTTCTGGTATCG	11424
30	CAGACGGCTGGGTGCTCGACGTACGGGGCGACCCTGCGCTATCTGGCATGC	11475
	TACATCCGTTTCGGGCGCTGGTTCATTGTTGCGGGGAATCTCCGCAGTCAG	11526
35	GTGGGGTTCTCCGTGATGTATCCGTAGCCCGTGAAAGAGGGGTCACCCACT	11577
	GCGGGGGGCCCCGGTACGGGATGGTTCGGCTTGTCACGAGATTCTTGTTTTTC	11628

CATTTCTTTCTTTTCACTCGGTCGCAGCGCCGGCTTGATGCATGCAAAGCA 11679
TCGATAGCTACGAACGGCCGCGATTCTTGAATCATGAATACATACGCTTGT 11730
5 GACGGGGCGCTCGCGAGAGCCGGCCCCAGGGATGGTTTACGCCTGCATTTA 11781
CGGTAAAGCGGCAAGGCGGCATGGCGCGCTGGCGGGCGGCTGGGCGTCGCGG 11832
10 CGCTGGGCCATGCTGGCGAGCCTGGCGCCGGCCGCnCGGGCAGCTyGTnAT 11883

15

20

25

30

35

The relative GC content of the FHA ORF is 67.5%. Examination of this nucleotide sequence for transcriptional start signals indicates possible -35 and -10 consensus regions, TGGTTTGAC and TATAAAT, separated by 23 base pairs, located 174 and 142 bp upstream of the beginning of the ORF, with transcriptional initiation beginning apparently to 30 to 75 bp from the initiation codon. A possible ribosomal binding site, GAGG, occurs 90 bp upstream of the ORF. Another possible ribosomal binding site, CTGG, occurs 11 bp in front of the third ATG. Further analysis of the nucleotide sequence reveals a region of alternating direct repeats of the pattern, ABABA, located between 1468 and 1746 bp from the left hand EcoRI site. Similar repeats are found in the predicted amino acid sequence corresponding to this same region.

Predicted Peptide Sequence

The predicted amino acid sequence of the FHA ORF is 3597 residues long, with a calculated MW of 368 kDa. This is substantially larger than published measured values. The composition of this sequence is alanine and glycine rich (27.0%) and is nearly identical to a previously published chemical analysis of the FHA amino acid composition (Sato et al., 1983, supra). The computed isoelectric point of the entire polypeptide is 6.79.

The concentration of charged residues in the FHA polypeptide chain is highest between positions 2000 and 2700. Hydrophobicity is highest in the N-terminal 300 residues and again at specific locations near residues 1800-2000 and 2400-2500. There is a highly predicted transmembrane helix between amino acid positions 44 and 69 with its transmembrane segment between residues 52 and 69.

One interesting feature of the predicted amino acid polypeptide is the sequence RRARR located at

position 1069. This highly arginine rich sequence is a likely site for trypsin-like proteolytic cleavage. N-terminal amino acid sequence determinations of several of the SDS-PAGE FHA peptide bands by other workers confirms that cleavage, in fact, occurs at this location. Analysis of the resultant two parts of the FHA peptide sequence demonstrates striking differences in chemical properties: The N-terminal 98kDa fragment is highly basic with a positive hydropathy score, whereas the C-terminal 140 kDa portion is a negatively charged acidic polypeptide which has a more hydrophilic overall composition. Polypeptides of these two sizes are dominant species on FHA Western immunoblots.

15 Cell Recognition Site

Located at amino acid position 1097 and again at position 2599 is the tripeptide sequence RGD. This sequence is known as a "cell recognition site" for the interaction of fibronectin and other eukaryotic extracellular matrix proteins with the integrin receptor family on a variety of eukaryotic cell surfaces (Pierschbacher and Ruoslahti, Proc. Natl. Acad. Sci. USA (1984) 81:5985-5988, Ruoslahti and Pierschbacher, Science (1987) 238:491-497). Secondary structure analysis of the polypeptide sequence adjacent to these two FHA RGD sites reveals that the first of these is highly predicted to be surface exposed, hydrophilic, and antigenic. Comparison of the FHA peptide sequence adjacent to this RGD site and the sequence surrounding the RGD in fibronectin shows identity at 7 of the 9 residues. Cleavage at the RRARR processing site would leave this first RGD sequence close to the N terminus of the 214 kDa polypeptide product.

35

In vitro Cell Adherence

The role of several virulence factors in mediating adherence of B. pertussis to Chinese Hamster Ovary cells was evaluated. Table 3 indicates the findings:

Table 3ADHERENCE OF B. pertussis STRAINS TO CHO CELLS

Strain	Pha	Fim2	Fim3	Mean adherent bacteria per CHO cell \pm SD (95% confidence interval)% Wt
BP536 (<u>vir</u> ⁺)	+	+	-	-363 \pm 111 (243-483) 100
BP537 (<u>vir</u> ⁻)	-	-	-	-2.55 \pm 2.8 (0.71-4.39) 0.7
BP101 (<u>fhaB</u> Δ 101)	-	+	-	-10.8 \pm 5.2 (7.67-13.9) 3.0
BP-B52 (<u>fim2B</u> 52, <u>fim3</u> ::Km)	+	-	-	-317 \pm 158 (146-488) 87.3
BP353 (<u>fhaA</u> ::Tn5)	+	-	-	-23.4 \pm 13.8 (13.3-33.5) 6.4
BP-TOX6 (<u>ptxA</u> Δ 6)	+	+	-	-405 \pm 102 (303-507) 112

The results described in the above section demonstrate that the gene encoding filamentous hemagglutinin of B. pertussis and the expressed gene product are now available in intact and modified forms, for use in diagnosis, prophylaxis and therapy of pertussis. Of particular interest is the use of the gene to prepare vaccines, where the protein may be used

by itself, as a fragment, as the intact expression product of the gene or the physiologically active fragment thereof, or in combination with other pertussis proteins, particularly with modified
5 pertussis toxin, or with proteins of other pathogens. The subject gene may be used to enhance the amount of the filamentous hemagglutinin present in a live or dead B. pertussis organism or to provide for the presence of the subject proteins in other organisms, where immune
10 response to more than one antigen is desired.

All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent
15 applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

The invention now being fully described, it
20 will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

25 .

30

35

WHAT IS CLAIMED IS:

1. A nucleic acid sequence of (1) less than about 15kbp encoding the B. pertussis fhaB gene; or (2) fragment thereof of at least about 15bp, or (3) fragment thereof joined to a nucleic acid sequence from other than B. pertussis; and free of the fhaA gene; and other than the sequence from 5625 to 5780 joined to other than an adjoining B. pertussis sequence.

2. A nucleic acid sequence according to Claim 1, wherein said sequence does not extend beyond the 5' transcriptional and translational control sequences and the termination region of said fhaB gene.

3. A nucleic acid sequence according to Claim 2, wherein said fragment is free of other nucleic acid or is directly joined to a nucleic acid sequence from other than B. pertussis.

4. A nucleic acid sequence according to Claim 1, wherein said sequence is an N-proximal sequence extending to at least about the sequence encoding RRARR.

5. A nucleic acid sequence according to Claim 1, wherein said sequence is the a-proximal sequence extending from about the sequence encoding RRARR.

6. A nucleic acid sequence according to Claim 1, comprising at least one of the sequences 3490 to 3590, 3840 to 3940, 5840 to 5940, or 9440 to 9540 or a fragment of at least 15bp thereof.

7. A nucleic acid sequence according to Claim 6, wherein said sequence is joined directly or indirectly to other than a B. pertussis sequence.

5 8. A DNA sequence encoding the B. pertussis fhaB gene or a fragment of at least 201 base pairs joined to at least one of a promoter or termination sequence other than the natural sequence and free of other genes of B. pertussis.

10

9. A DNA sequence according to Claim 8, comprising at least one of the sequences 3490 to 3590, 3840 to 3940, 5840 to 5940, or 9440 to 9540.

15

10. A DNA sequence according to Claim 8, wherein said sequence is the N-proximal sequence extending to at least about the sequence encoding RRARR.

20

11. A DNA sequence according to Claim 8, wherein said sequence is the C-proximal sequence extending from about the sequence encoding RRARR.

25

12. A vector comprising a replication system functional in a prokaryotic host and a DNA sequence according to Claim 8.

30

13. A vector according to Claim 12, wherein said vector comprises a marker for selection.

35

14. A vector according to Claim 12, wherein said sequence is joined to a promoter and terminator sequence functional for expression in a prokaryotic host.

15. A vector according to Claim 14, wherein said promoter is the natural promoter.

16. A vector according to Claim 14, wherein said promoter is other than the natural promoter.

5 17. A transformed prokaryotic cell comprising a DNA sequence comprising the fhaB gene or fragment thereof of at least 15bp joined to other than the fhaA gene and other than the sequence from 5625 to 5780, as a result of in vitro introduction of said DNA sequence
10 into a precursor prokaryotic cell, and progeny of said transformed prokaryotic cell.

15 18. A transformed prokaryotic cell according to Claim 17, wherein said precursor cell is B. pertussis.

 19. A method for producing a peptide cross-reactive with the filamentous hemagglutinin of B. pertussis, said method comprising:
 growing a transformed prokaryotic host
20 comprising an fhaB expression cassette capable of expression in said host, whereby said peptide is expressed.

 20. A method according to Claim 19, wherein
25 said peptide comprises a fragment of at least 9 amino acids of said filamentous hemagglutinin.

 21. A method according to Claim 20, wherein
30 said peptide is the C-terminal portion of the fhaB gene.

 22. A vaccine comprising a peptide cross-reactive with the filamentous hemagglutinin of B. pertussis prepared by the method comprising:
35 growing a transformed prokaryotic host comprising an fhaB expression cassette capable of

expression in said host, whereby said peptide is expressed.

23. A vaccine according to Claim 22, further
5 comprising a peptide cross-reactive with B. pertussis
endotoxin.

24. A vaccine according to Claim 22, wherein
10 said peptide is cross-reactive with the A subunit.

15

20

25

30

35

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US89/04732

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(5): C12P 21/00; C07H 15/12; C07K 13/00

US: 435/68; 536/27; 530/350

II. FIELDS SEARCHED

Minimum Documentation Searched ⁷

Classification System	Classification Symbols
U.S.	435/68, 70, 91, 172.1, 172.3, 320; 536/27 935/19, 26, 41, 55, 65, 73 530/350

Documentation Searched other than Minimum Documentation
to the extent that such Documents are included in the Fields Searched ⁸

CHEMICAL ABSTRACTS DATA BASE (CAS) 1967-1990.

KEYWORDS: BORDETELLA PERTUSSIS, FHA, HEMAGGLUTININ, GENE

III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹

Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	Infection and Immunity, volume 55, issued January 1987, (BROWN et al) "Cloning of the filamentous hemagglutinin of <u>Bordetella pertussis</u> and its expression in <u>Escherichia coli</u> " see pages 154-161, see especially, the abstract and figure 4.	1-21
X	Journal of Bacteriology, volume 170, issued July 1988, (STIBITZ et al) "Genetic analysis of a region of the <u>Bordetella pertussis</u> chromosome encoding filamentous hemagglutinin and the pleiotropic regulatory locus vir", see pages 2904-2913, see especially the abstract and figure 1.	1-21
Y	FEMS Microbiology Letters, volume 37, issued September 1986, (MATTEI et al) "Molecular cloning of a coding sequence of <u>Bordetella pertussis</u> filamentous hemagglutinin gene", see pages 73-77, see especially, the abstract and page 77.	1-21

^{*} Special categories of cited documents: ¹⁰

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

16 January 1990

International Searching Authority

ISA/US

Date of Mailing of this International Search Report

30 JAN 1990

Signature of Authorized Officer

JOAN ELLIS

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Proceedings of the Fourth International Symposium on Pertussis, Develop. biol. Standard. Volume 61 issued 1985 (REISER et al) " <u>Bordetella pertussis</u> filamentous hemagglutinin gene: Molecular cloning of a potential coding Sequence " see pages 265-271, see especially, the abstract.	1-21
X, P	Proceedings of the National Academy of Sciences, U.S.A., volume 86, issued April 1989 (RELMAN et al) "Filamentous hemagglutinin of <u>Bordetella pertussis</u> : Nucleotide sequence and crucial role in adherence", see pages 2637-2641, see especially, the abstract and figure 2.	1-21
Y	EP 0,287,732 A1 (CHAZANO et al) 26 October 1988, see abstract.	22-24
Y	EP 0,175,841 A2 (GINNAGA et al) 02 April 1986, see abstract.	22-24
Y	EP 0,231,083 A2 (ROBINSON et al) 05 August 1987, see abstract.	